Ovarian cancer drug safety checked in 354 patients
NCT ID NCT05021562
First seen Jan 07, 2026 · Last updated May 13, 2026 · Updated 23 times
Summary
This study followed 354 people with ovarian cancer who were taking niraparib (Zedula) capsules daily as part of their normal care. The main goal was to watch for side effects like low blood cell counts, high blood pressure, and other serious issues over one year. Researchers did not change how patients were treated, they just recorded what happened to better understand the drug's safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda Selected Site
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.